معرفی
Dr. Philipp Schlegel serves as a Senior Physician in the Department of Cardiology, Angiology, and Pulmonology at Heidelberg University Hospital, where he also holds the position of Medical Director of the VAD Outpatient Clinic and leads the Working Group on Molecular Target Structures in Heart Diseases. His academic career has been deeply rooted at Heidelberg University, where he completed his medical studies and subsequent specialization.
Dr. Schlegel's research spans both molecular and clinical cardiology, with a particular focus on developing gene therapy-based approaches for heart failure treatment and optimizing interventional procedures for cardiac gene transfer. His clinical work centers on structural heart disease interventions, advanced echocardiography techniques, and management of advanced and terminal heart failure cases including cardiac transplantation. His dual expertise in molecular mechanisms and clinical applications positions him at the forefront of translational cardiology research.
- Dresden Heart Circulation Days Research Award (2022)
- Clinician-Scientist Program of the German Cardiac Society (DGK) (2020)
- Research Scholarship of the German Cardiac Society (DGK) (2017)
- Graduate Scholarship of the Novartis Foundation for Therapeutic Research (2014)
Dr. Schlegel's work bridges basic science and clinical practice through his leadership of the Working Group on Molecular Target Structures in Heart Diseases. His research has secured funding from major German cardiology organizations including the German Cardiac Society. His recent publications demonstrate a strong focus on structural heart disease, particularly tricuspid valve pathology, as evidenced by his contributions to the EuroTR Registry studies examining tricuspid regurgitation disease stages and treatment outcomes.
As Medical Director of the VAD Outpatient Clinic, Dr. Schlegel oversees comprehensive care for patients with ventricular assist devices, integrating his expertise in advanced heart failure management with cutting-edge mechanical circulatory support technologies. His clinical leadership extends to developing specialized protocols for structural heart disease interventions and echocardiographic assessment.
